Identification of driver mutations in lung cancer: First step in personalized cancer

Targeted Oncology

Volumn 8, Issue 1, 2013, Pages 3-14

  Planchard, David ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

ALK; EGFR; Mutation; NSCLC; Personalized

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DASATINIB; DISCOIDIN DOMAIN RECEPTOR 2; DOCETAXEL; EML4 ALK PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GEFITINIB; GEMCITABINE; HYBRID PROTEIN; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PACLITAXEL; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE LKB1; PROTEIN RET; SCATTER FACTOR RECEPTOR; SOMATOMEDIN C; TRANSCRIPTION FACTOR SOX2; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHROMOSOMAL LOCALIZATION; DRIVER MUTATION; DRUG EFFICACY; FINE NEEDLE ASPIRATION BIOPSY; GENE FREQUENCY; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULAR DIAGNOSIS; MOLECULARLY TARGETED THERAPY; MUTATIONAL ANALYSIS; NONHUMAN; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; MUTATION;

EID: 84874934597     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0263-z     Document Type: Article

References (102)

1. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543-3551
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-2550
3. Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12(2):175-180
4. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304(5676):1497-1500
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350(21):2129-2139
6. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011-1019
7. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355(23):2408-2417
8. Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169-181
9. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S et al (1993) Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(10 Suppl):2379-2385
10. Hirsch FR, Dziadziuszko R, Thatcher N, Mann H, Watkins C, Parums DV et al (2008) Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer. Cancer 112(5):1114-1121
11. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al (2004) EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36):13306-13311
12. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339-346
13. Tam IY, Chung LP, Suen WS, Wang E, Wong MC, Ho KK et al (2006) Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res 12(5):1647-1653
14. Cheng L, Alexander RE, Maclennan GT, Cummings OW, Montironi R, Lopez-Beltran A et al (2012) Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol 25(3):347-369
15. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS (2001) The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12(6):745-760
16. Pao W, Miller VA (2005) Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23(11):2556-2568
17. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S et al (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23(11):2513-2520
18. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U et al (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23(28):6829-6837
19. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V et al (2011) Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 29(21):2866-2874
20. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C et al (2009) Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361(10):958-967
21. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
22. Lee JS, Park K, Kim SW, Lee DH, Kim HT, Ham JY (2009) A randomized phase III study of gefitinib (IRESSATM) versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung. J Thorac Oncol 4(9 suppl1):S283-S284, Abstract PRS.4
23. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388
24. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121-128
25. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12(8):735-742
26. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239-246
27. Yang J-C, Schuler M-H, Yamamoto N, O'Byrne K-J, Hirsh V, Mok T et al. (2012) LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol 30 (suppl; abstr LBA7500)
28. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521-529
29. Mok T, Spigel D, Park K, Socinski M, Tung S, Kim D-W et al. (2010) Efficacy and safety of PF299804 as first-line treatment of patients with advanced NSCLC selected for activating mutation of epidermal growth factor receptor (EGFR). Annals Oncol 21 ((suppl. 8): [abstract LBA18].)
30. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al (2005) EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352(8):786-792
31. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al (2005) Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2(3):e73
32. Yang C, Shih J, Su W, Hsia T, Tsai C, Ou SI et al (2010) A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2). J Clin Oncol 28:15s (suppl; abstr 7521)
33. Janjigian Y, smit EF, Horn L, Groen JJM, Camidge DR, Gettinger S (2012) Activity of afatinib/cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors. ESMO, abst 12270
34. Inukai M, Toyooka S, Ito S, Asano H, Ichihara S, Soh J et al (2006) Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66(16):7854-7858
35. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV et al (2008) Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 359(4):366-377
36. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S et al (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118(7):2609-2619
37. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L et al (2007) MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104(52):20932-20937
38. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043
39. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P et al (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 75:75ra26
40. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N et al (2008) PIK3CA mutations and copy number gains in human lung cancers. Cancer Res 68(17):6913-6921
41. Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B et al (2002) Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86(9):1449-1456
42. De Greve J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J et al (2012) Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer 76(1):123-127
43. Cappuzzo F, Bemis L, Varella-Garcia M (2006) HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med 354(24):2619-2621
44. Kelly RJ, Carter C, Giaccone G (2010) Personalizing therapy in an epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer using PF-00299804 and trastuzumab. J Clin Oncol 28(28):e507-e510
45. Iwahara T, Fujimoto J, Wen D, Cupples R, Bucay N, Arakawa T et al (1997) Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 14(4):439-449
46. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, Shapiro DN, Saltman DL et al (1994) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 263(5151):1281-1284
47. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448(7153):561-566
48. Choi YL, Takeuchi K, Soda M, Inamura K, Togashi Y, Hatano S et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68(13):4971-4976
49. Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M et al (2008) EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. J Thorac Oncol 3(1):13-17
50. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS et al (2009) Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 27(26):4247-4253
51. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693-1703
52. Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ et al (2012) Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 18(5):1472-1482
53. Horn L, Pao W (2009) EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27(26):4232-4235
54. Kim D-W, Ahn M-J, Shi Y, De Pas T-M, Yang P-C, Riely G-J et al. (2012) Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 30 (suppl; abstr 7533)
55. Shaw AT, Kim D-W, Nakagawa K, Seto TC, L., Ahn M-J, Tassell V et al. (2012) Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALKpositive non-small cell lung cancer (NSCLC) (PROFILE 1007) ESMO congress abst: LBA1
56. Yang P, Kulig K, Boland JM, Erickson-Johnson MR, Oliveira AM, Wampfler J et al (2012) Worse disease-free survival in never-smokers with ALK+ lung adenocarcinoma. J Thorac Oncol 7(1):90-97
57. Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363(18):1734-1739
58. Sasaki T, Koivunen J, Ogino A, Yanagita M, Nikiforow S, Zheng W et al (2011) A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 71(18):6051-6060
59. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT et al (2012) ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 30(8):863-870
60. Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC et al (2010) KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 69(3):272-278
61. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA et al (2008) Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 14(18):5731-5734
62. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9(10):962-972
63. Pao W, Wang TY, Riely GJ, Miller VA, Pan Q, Ladanyi M et al (2005) KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2(1):e17
64. O'Byrne KJ, Gatzemeier U, Bondarenko I, Barrios C, Eschbach C, Martens UM et al (2011) Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 12(8):795-805
65. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM et al (2011) Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. J Clin Oncol 29(31):4113-4120
66. Zhu CQ, da Cunha SG, Ding K, Sakurada A, Cutz JC, Liu N et al (2008) Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 26(26):4268-4275
67. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069-1075
68. Pasi A. Janne, Alice Tsang Shaw, Jose Rodrigues Pereira, Gaelle Jeannin, Johan Vansteenkiste, Carlos H. Barrios et al. (2012) Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC). J Clin Oncol suppl; abstr 7503 (30)
69. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949-954
70. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG et al (2011) Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 29(15):2046-2051
71. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H et al (2006) PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer 54(2):209-215
72. Hammerman PS, Hayes DN, Wilkerson MD, Schultz N, Bose R, Chu A et al (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489(7417):519-525
73. Kawano O, Sasaki H, Okuda K, Yukiue H, Yokoyama T, Yano M et al (2007) PIK3CA gene amplification in Japanese non-small cell lung cancer. Lung Cancer 58(1):159-160
74. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM et al (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448(7152):439-444
75. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S et al (2008) Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle 7(5):665-669
76. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL et al (2002) Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res 8(5):1178-1184
77. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA et al (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res 65(4):1479-1488
78. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D et al (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29(24):3307-3315
79. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR et al. (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29 (suppl; abstr 7505)
80. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW et al (2011) Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 6(5):942-946
81. Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y et al (2007) Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 26(40):5911-5918
82. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8(11):1439-1452
83. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2(62):62ra93
84. Dziadziuszko R, Merrick DT, Witta SE, Mendoza AD, Szostakiewicz B, Szymanowska A et al (2010) Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 28(13):2174-2180
85. Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F et al (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15):2516-2522
86. Jassem J LC, Karp DD (2010) Randomized, open label, phase III trial of figitumumab in combinations with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 28 (15suppl):abstract 7500
87. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1):78-89
88. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D et al (2010) SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One 5(1):e8960
89. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238-1242
90. Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T et al (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18(3):375-377
91. Wang R, Hu H, Pan Y, Li Y, Ye T, Li C et al (2012) RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol 30(35):4352-4359
92. Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G et al (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 62(24):7284-7290
93. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A et al (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44-53
94. Kris MG, Johnson BE, DJ K (2011) Identification of driver mutations in tumor specimens from 1000 patients with lung adenocarcinoma: the NCI's Lung Cancer Mutation Consortium (LCMC). J Clin Oncol 29:(Suppl, abstract CRA 7506)
95. Planchard D, A. Rahal, L. Lacroix, M. Ngocamus, N. Auger, P. Saulnier et al. (2012) Upfront genomic testing for patients with non-small cell lung cancer (NSCLC) receiving first-line platinum-based regimen: preliminary result of the MSN study. ESMO-ELCC Abst: 810
96. Nowak F, Soria JC, Calvo F (2012) Tumour molecular profiling for deciding therapy-the French initiative. Nat Rev Clin Oncol 9(8):479-486
97. Perez-Moreno P, Brambilla E, Thomas R, Soria JC (2012) Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 18(9):2443-2451
98. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366(10):883-892
99. Chen ZY, Zhong WZ, Zhang XC, Su J, Yang XN, Chen ZH et al (2012) EGFR mutation heterogeneity and the mixed response to EGFR tyrosine kinase inhibitors of lung adenocarcinomas. Oncologist 17(7):978-985
100. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V et al (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99(6):923-929
101. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M (2009) EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 15(14):4554-4560
102. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99(5):929-935